Isabelle Ayoub1, Jessica Nelson2,3, Brad H Rovin2. 1. Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, OH, USA. isabelle.ayoub@osumc.edu. 2. Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, OH, USA. 3. Division of Nephrology, Nationwide Children's Hospital, Columbus, OH, USA.
Abstract
PURPOSE OF REVIEW: Lupus nephritis is a frequent complication of systemic lupus erythematosus and is more common and severe in children. This is a disease of the immune system characterized by T cell, B cell, and complement activation, as well as immune complex formation and deposition. The introduction of steroids and later cyclophosphamide transformed lupus nephritis from a fatal to a treatable condition. However, the standard therapies currently used for treatment carry significant toxicity and chronic kidney disease still remains a far too frequent outcome. To address these issues, we will review current and emerging induction therapies in LN. RECENT FINDINGS: Several clinical trials have been undertaken to test more effective and safer drugs, often targeting mechanistic disease pathways. At present, it is difficult to identify an induction regimen that is more effective and less toxic than the standard of care; however, we believe continuing efforts in drug development will bring breakthrough agents to clinics.
PURPOSE OF REVIEW: Lupus nephritis is a frequent complication of systemic lupus erythematosus and is more common and severe in children. This is a disease of the immune system characterized by T cell, B cell, and complement activation, as well as immune complex formation and deposition. The introduction of steroids and later cyclophosphamide transformed lupus nephritis from a fatal to a treatable condition. However, the standard therapies currently used for treatment carry significant toxicity and chronic kidney disease still remains a far too frequent outcome. To address these issues, we will review current and emerging induction therapies in LN. RECENT FINDINGS: Several clinical trials have been undertaken to test more effective and safer drugs, often targeting mechanistic disease pathways. At present, it is difficult to identify an induction regimen that is more effective and less toxic than the standard of care; however, we believe continuing efforts in drug development will bring breakthrough agents to clinics.
Authors: Hilario J Ramos; Ann M Davis; Alexander G Cole; John D Schatzle; James Forman; J David Farrar Journal: Blood Date: 2009-03-18 Impact factor: 22.113
Authors: F A Houssiau; C Vasconcelos; D D'Cruz; G D Sebastiani; E de Ramon Garrido; M G Danieli; D Abramovicz; D Blockmans; A Cauli; H Direskeneli; M Galeazzi; A Gül; Y Levy; P Petera; R Popovic; R Petrovic; R A Sinico; R Cattaneo; J Font; G Depresseux; J-P Cosyns; R Cervera Journal: Ann Rheum Dis Date: 2010-01 Impact factor: 19.103
Authors: Andreas Kuglstatter; Francis Mueller; Eric Kusznir; Bernard Gsell; Martine Stihle; Ralf Thoma; Joerg Benz; Launa Aspeslet; Derrick Freitag; Michael Hennig Journal: Acta Crystallogr D Biol Crystallogr Date: 2011-01-15
Authors: M Newling; R H Fiechter; L Sritharan; W Hoepel; J A van Burgsteden; A E Hak; R F van Vollenhoven; M G H van de Sande; D L P Baeten; J den Dunnen Journal: Clin Exp Immunol Date: 2019-10-07 Impact factor: 4.330